A Drug Interaction Study of Danicopan

Study identifier:ACH471-017

ClinicalTrials.gov identifier:NCT04709094

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Three-Part Phase 1 Study to Evaluate the Potential Drug Interaction between ACH-0144471 and Warfarin, Bupropion, and Ethinyl Estradiol and Norethindrone (Oral Contraceptive) in Healthy Adult Subjects

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Danicopan, Warfarin, Bupropion, Ethinyl Estradiol/Norethindrone

Sex

All

Actual Enrollment

52

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 28 Jul 2019
Primary Completion Date: 14 Oct 2019
Study Completion Date: 17 Apr 2020

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Basic Science

Verification:

Verified 01 Mar 2024 by Alexion Pharmaceuticals

Sponsors

Alexion Pharmaceuticals

Collaborators

Achillion, a wholly owned subsidiary of Alexion, Celerion

Inclusion and exclusion criteria